Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report

Leukemia

Volumn 14, Issue 12, 2000, Pages 2257-2266

  Vilmer, E ^a   Suciu, S ^b   Ferster, A ^c   Bertrand, Y ^d   Cave H ^a   Thyss, A ^e   Benoit, Y ^f   Dastugue, N ^g   Fournier, M ^h   Souillet, G ^d   Manel, A M ^d   Robert, A ⁱ   Nelken, B ^h   Millot, F ^j   Lutz, P ^k   Rialland, X ^l   Mechinaud, F ^m   Boutard, P ⁿ   Behar, C ^o   Chantraine, J M ^p   Plouvier, E ^q   Laureys, G ^f   Brock, P ^r   Uyttebroeck, A ^r   Margueritte, G ^s   Plantaz, D ^t   Norton, L ^u   Francotte, N ^v   Gyselinck, J ^w   Waterkeyn, C ^b   Solbu, G ^b   Philippe, N ^d   Otten, J ^x   more..

^a HÔPITAL ROBERT DEBRÉ   (France)

^b EORTC DATA CENTER   (Belgium)

^c HUDE   (Belgium)

^d HÔPITAL DEBROUSSE   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g CHU PURPAN   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL DES ENFANTS   (France)

^j J Bernard Hospital   (France)

^k Hautepierre ^*  (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m HÔTEL DIEU   (France)

ⁿ CAEN UNIVERSITY HOSPITAL   (France)

^o AMERICAN HOSPITAL OF PARIS   (France)

^p Centre Hospitalier Regional de La Citadelle   (Belgium)

^q HÔPITAL SAINT JACQUES   (France)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s Department of Vascular and Thoracic Surgery Arnaud   (France)

^t CHU La Tronche and University   (France)

^u HOSPITAL DE SÃO JOÃO   (Portugal)

^v Esperance Clinic   (Belgium)

^w MIDDELHEIM HOSPITAL   (Belgium)

^x UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

Acute lymphoblastic leukemia; Childhood; EORTC; Long term follow up

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; STEROID; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ERWINIA; ESCHERICHIA COLI; FEMALE; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; INFANT; INFORMATION PROCESSING; LEUKOCYTE COUNT; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE;

EID: 17744400282     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401960     Document Type: Article

References (25)

1. Treatment of standard risk (SR) acute lymphoblastic leukemia (ALL) with the BFM protocol with or without cyclophosphamide: Preliminary results of a randomized trial (EORTC nr 58831)
2. Treatment of medium and high risk (M-HR) acute lymphoblastic leukemia (ALL) with or without radiotherapy (RXT): Results of a randomized trial (EORTC nr 58832)
3. Value of high dose Ara-C during the interval-therapy of a BFM like protocol in increased risk ALL and NHL stage III and IV patients: Results of the EORTC 58881 trial
4. Value of high-dose Ara-C during the interval-therapy of a BFM-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the EORTC 58881 randomized phase III trial
5. The value of 6-MP i.v. during maintenance treatment in childhood acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL): Results of the randomized phase III trial 58881 of EORTC Childhood Leukemia Cooperative Group (CLCG)
6. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children
7. Comparative toxicity and efficacy of E. coli-asparaginase and Erwinia-asparaginase in childhood lymphoid malignancies: Results of an EORTC-CLCG phase III randomized trial
8. Abschatzung der tumorzellmasse bei der akuten lymphoblastischen leukamie im kindesalter: Prognostische bedeuting und pratische Anwendung
9. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracycline and cranial radiotherapy: Results of trial ALL-BFM 90
10. Low leucocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia
11. The BFM relapse studies in childhood ALL: Concepts of two multicenter trials and results after 21/2 years
12. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia
13. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
14. Treatment outcome in infant acute lymphoblastic leukemia
15. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia. Results and conclusions of the multicenter trial ALL-BFM 86
16. A semi-quantitative method using TcRγδ and IgH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia
17. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy
18. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
19. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
20. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study
21. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
22. Comparative pharmacokinetics studies of three asparaginase preparations
23. Monitoring of asparaginase activity and asparaginase levels in children on different asparaginase preparations